Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Jon C. Ogg | Jan 27, 2016 at 12:55 PM EST

Anthem Shows Health Care Costs Eating Into Profits

Anthem is the latest health insurance provider to have some concerns around its earnings report.

Jon C. Ogg | Jan 27, 2016 at 12:40 PM EST

Regeneron Downgrade Highlights at Least Some Risks

Regeneron Pharmaceuticals seems to have held up rather well against an analyst downgrade on Wednesday.

Chris Lange | Jan 27, 2016 at 9:15 AM EST

How Anthem Fell Short on Earnings and Membership

Anthem released a disappointing fourth-quarter earnings report before the markets opened Wednesday.

Chris Lange | Jan 27, 2016 at 8:35 AM EST

How Biogen Won at Earnings in Q4

Biogen reported better-than-expected fourth-quarter financial results before the markets opened on Wednesday.

Chris Lange | Jan 26, 2016 at 1:50 PM EST

What to Expect From Biogen Earnings

Biogen is set to report its fourth-quarter financial results before the markets open Wednesday.

Paul Ausick | Jan 26, 2016 at 12:10 PM EST

Centene Data Debacle Affects 950,000 Customers

Centene said on Monday that it is conducting an "ongoing comprehensive internal search for six hard drives" that failed to…

Chris Lange | Jan 26, 2016 at 11:40 AM EST

Tactile Systems Files for IPO

Tactile Systems Technology has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).

Chris Lange | Jan 26, 2016 at 10:15 AM EST

Relypsa Soars on Positive Phase 1 Results

Relypsa rose early in Monday’s session as the result of positive results from its Phase 1 in vivo studies evaluating…

Chris Lange | Jan 26, 2016 at 9:05 AM EST

Johnson & Johnson Kicks Off 2016 With Solid Earnings and Guidance

Johnson & Johnson reported its fourth-quarter financial results before the markets opened on Tuesday.

Chris Lange | Jan 25, 2016 at 12:40 PM EST

What to Look for in Johnson & Johnson Earnings

Johnson & Johnson is set to release its fourth-quarter financial results before the markets open Tuesday.

Chris Lange | Jan 25, 2016 at 11:35 AM EST

Could This Merck Deal Be the Turning Point for Affimed?

Affimed shares rose on Monday following the announcement of a collaboration in immuno-oncology with biotech giant Merck.

Chris Lange | Jan 25, 2016 at 9:15 AM EST

Why OncoMed’s Update Could Crater the Stock

OncoMed Pharmaceuticals saw its stock sink early Monday morning following an update from its Phase 2 Alpine study.

Chris Lange | Jan 22, 2016 at 11:55 AM EST

Agile Therapeutics Announces Pricing for Secondary Offering

Agile Therapeutics fell in Friday’s session, despite the broad markets taking off, after the company announced the pricing for its…

Chris Lange | Jan 21, 2016 at 9:15 AM EST

Why Alkermes Top-Line Results Might Not Be as Bad as Once Thought

Alkermes absolutely tanked early Thursday morning on less than favorable preliminary top-line results from the first two of three Phase…

Chris Lange | Jan 20, 2016 at 11:45 AM EST

Despite Market and Sector Risks, Why Credit Suisse Now Loves Top Biotechs

Credit Suisse sees solid fundamentals, despite a harsh market landscape, for large-cap biotech firms. It initiated several top biotech stocks…

1 … 226 227 228 229 230 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Anthem Shows Health Care Costs Eating Into Profits

Regeneron Downgrade Highlights at Least Some Risks

How Anthem Fell Short on Earnings and Membership

How Biogen Won at Earnings in Q4

What to Expect From Biogen Earnings

Centene Data Debacle Affects 950,000 Customers

Tactile Systems Files for IPO

Relypsa Soars on Positive Phase 1 Results

Johnson & Johnson Kicks Off 2016 With Solid Earnings and Guidance

What to Look for in Johnson & Johnson Earnings

Could This Merck Deal Be the Turning Point for Affimed?

Why OncoMed’s Update Could Crater the Stock

Agile Therapeutics Announces Pricing for Secondary Offering

Why Alkermes Top-Line Results Might Not Be as Bad as Once Thought

Despite Market and Sector Risks, Why Credit Suisse Now Loves Top Biotechs

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

3 Dividend Stocks Built for Retirement to Buy in June

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

A $900,000 Nest Egg at 65 Only Translates to About $36,000 in Real Annual Spending After Taxes and Inflation

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

Health and Healthcare Articles

All Health and Healthcare Articles

Anthem Shows Health Care Costs Eating Into Profits

Regeneron Downgrade Highlights at Least Some Risks

How Anthem Fell Short on Earnings and Membership

How Biogen Won at Earnings in Q4

What to Expect From Biogen Earnings

Centene Data Debacle Affects 950,000 Customers

Tactile Systems Files for IPO

Relypsa Soars on Positive Phase 1 Results

Johnson & Johnson Kicks Off 2016 With Solid Earnings and Guidance

What to Look for in Johnson & Johnson Earnings

Could This Merck Deal Be the Turning Point for Affimed?

Why OncoMed’s Update Could Crater the Stock

Agile Therapeutics Announces Pricing for Secondary Offering

Why Alkermes Top-Line Results Might Not Be as Bad as Once Thought

Despite Market and Sector Risks, Why Credit Suisse Now Loves Top Biotechs

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

3 Dividend Stocks Built for Retirement to Buy in June

Featured Reads

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

A $900,000 Nest Egg at 65 Only Translates to About $36,000 in Real Annual Spending After Taxes and Inflation